FCGRT and myasthenia gravis: Evidence from preclinical studies supported the concept of inhibiting FcRn in IgG-driven autoimmune disorders.16,17 Subsequent randomized, placebo-controlled phase II and phase III trials in generalized MG have shown efgartigimod to be effective as well as safe.18,19 In the pivotal ADAPT trial, efgartigimod was associated with a favorable clinical response compared to placebo leading to regulatory approval for use in generalized AChRAb positive MG with a good safety profile.